118 related articles for article (PubMed ID: 34083274)
1. HLA-DR and CD74 Expression and the Immune Microenvironment in Renal Cell Carcinoma.
Miura Y; Anami T; Yatsuda J; Motoshima T; Oka S; Suyama K; Inoshita N; Kinowaki K; Urakami S; Kamba T; Komohara Y
Anticancer Res; 2021 Jun; 41(6):2841-2848. PubMed ID: 34083274
[TBL] [Abstract][Full Text] [Related]
2. MHC class II antigen-associated invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host.
Saito T; Kimura M; Kawasaki T; Sato S; Tomita Y
Cancer Lett; 1997 May; 115(1):121-7. PubMed ID: 9097987
[TBL] [Abstract][Full Text] [Related]
3. HLA class I and II antigens expression in patients with renal cell carcinoma.
Ozgur BC; Gonenc F; Yazicioglu AH
Saudi J Kidney Dis Transpl; 2009 Jan; 20(1):97-101. PubMed ID: 19112225
[TBL] [Abstract][Full Text] [Related]
4. MHC class II antigen-associated invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host.
Saito T; Kimura M; Kawasaki T; Sato S; Tomita Y
Cancer Lett; 1996 Dec; 109(1-2):15-21. PubMed ID: 9020898
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation with clinical and histopathological data.
Brasanac D; Marković-Lipkovski J; Hadzi-Djokić J; Müller GA; Müller CA
Neoplasma; 1999; 46(3):173-8. PubMed ID: 10613593
[TBL] [Abstract][Full Text] [Related]
6. [Expression of HLA class II antigen-associated invariant chain on renal cell cancer].
Saito T; Tomita Y; Kimura M; Nishiyama T; Sato S
Nihon Hinyokika Gakkai Zasshi; 1993 Jun; 84(6):1036-40. PubMed ID: 8345720
[TBL] [Abstract][Full Text] [Related]
7. Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls.
Goebel S; Kehlen A; Bluemke K; Altermann W; Schlaf G; Fischer K; Fornara P; Wullich B; Wach S; Taubert H
Cancer Immunol Immunother; 2017 May; 66(5):565-571. PubMed ID: 28184970
[TBL] [Abstract][Full Text] [Related]
8. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
9. [Major histocompatibility complex class II antigens on renal cell cancer--immunohistochemical study and effect on their expression by interferon].
Tomita Y
Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1079-86. PubMed ID: 2120500
[TBL] [Abstract][Full Text] [Related]
10. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas.
Dengjel J; Nastke MD; Gouttefangeas C; Gitsioudis G; Schoor O; Altenberend F; Müller M; Krämer B; Missiou A; Sauter M; Hennenlotter J; Wernet D; Stenzl A; Rammensee HG; Klingel K; Stevanović S
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4163-70. PubMed ID: 16857787
[TBL] [Abstract][Full Text] [Related]
11. Constitutive intracellular expression of human leukocyte antigen (HLA)-DO and HLA-DR but not HLA-DM in trophoblast cells.
Ranella A; Vassiliadis S; Mastora C; Valentina M; Dionyssopoulou E; Athanassakis I
Hum Immunol; 2005 Jan; 66(1):43-55. PubMed ID: 15620461
[TBL] [Abstract][Full Text] [Related]
12. Interaction of HLA-DR and CD74 at the cell surface of antigen-presenting cells by single particle image analysis.
Karakikes I; Morrison IE; O'Toole P; Metodieva G; Navarrete CV; Gomez J; Miranda-Sayago JM; Cherry RJ; Metodiev M; Fernandez N
FASEB J; 2012 Dec; 26(12):4886-96. PubMed ID: 22889831
[TBL] [Abstract][Full Text] [Related]
13. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.
Antohe I; Tanasa MP; Dăscălescu A; Dănăilă C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Cianga P
Immunobiology; 2021 Jan; 226(1):152049. PubMed ID: 33352400
[TBL] [Abstract][Full Text] [Related]
14. Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.
Moldenhauer G; Henne C; Karhausen J; Möller P
Immunology; 1999 Mar; 96(3):473-84. PubMed ID: 10233730
[TBL] [Abstract][Full Text] [Related]
15. Expression of invariant chain (CD 74) and major histocompatibility complex (MHC) class II antigens in the human fetus.
Badve S; Deshpande C; Hua Z; Lögdberg L
J Histochem Cytochem; 2002 Apr; 50(4):473-82. PubMed ID: 11897800
[TBL] [Abstract][Full Text] [Related]
16. Cell-surface expression of human histocompatibility leucocyte antigen (HLA) class II-associated invariant chain (CD74) does not always correlate with cell-surface expression of HLA class II molecules.
Wilson KM; Labeta MO; Pawelec G; Fernandez N
Immunology; 1993 Jun; 79(2):331-5. PubMed ID: 8344710
[TBL] [Abstract][Full Text] [Related]
17. HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma.
Oldford SA; Robb JD; Watson PH; Drover S
Int J Cancer; 2004 Nov; 112(3):399-406. PubMed ID: 15382064
[TBL] [Abstract][Full Text] [Related]
18. Decreased HLA-DR antigen-associated invariant chain (CD74) mRNA expression predicts mortality after septic shock.
Cazalis MA; Friggeri A; Cavé L; Demaret J; Barbalat V; Cerrato E; Lepape A; Pachot A; Monneret G; Venet F
Crit Care; 2013 Dec; 17(6):R287. PubMed ID: 24321376
[TBL] [Abstract][Full Text] [Related]
19. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma.
Kowalczyk D; Skorupski W; Kwias Z; Nowak J
Br J Urol; 1997 Oct; 80(4):543-7. PubMed ID: 9352689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
